Summary
Antiphospholipid antibody syndrome (APS) is characterised by the presence of frequently
recurring venous and/or arterial thrombosis, abortions and repeated evidence of
lupus anticoagulants and/or anticardiolipin (aCL)-antibodies. The presence of
lupus anticoagulants and/or high levels of aCL-antibodies in particular increases
the risk of thrombosis. At present there are several models for the systemic and
cell-damaging pathogenesis of phospholipid-antibodies. Where there are repeated
occurrences of thrombo-embolic complications long-term anticoagulant treatment
is indicated. For patients who have APS in pregnancy, the use of low-molecular
heparin and acetylsalicylic acid (ASS) is recommended. According to recent
research, a large number of antibodies can be found in APS patients, which are
directed against phospholipids and plasmaproteins, but partly also against individual
genetic polymorphism, which suggests focussing in future on the genetic basis
of APS as well as on influencing „auto-immune thrombosis” by modulating the immune
system.
Literatur
- 1
Alarcón-Segovia D, Boffa M C, Branch W. et al .
Prophylaxis of the antiphospholipid syndrome: a consensus report.
Lupus.
2003;
12
499-503
- 2
Alarcón-Segovia D, Pérez-Vázquez M E, Villa A R, Drenkard C, Cabiedes J.
Preliminary classification criteria for the antiphospholipid syndrome within
systemic lupus erythematosus.
Semin Arthritis Rheum.
1992;
21
275-286
- 3
Alliot C, Messouak D, Albert F.
Correction of thrombocytopenia with aspirin in the primary antiphospholipid
syndrome.
Am J Hematol.
2001;
68
215
- 4
Al-Saeed A. et al .
The development of antiphospholipid antibodies in haemophilia is linked to infection
with hepatitis C.
Br J Haematol.
1994;
88
845-848
- 5
al Sayegh F A, Ensworth S, Huang S, Stein H B, Klinkhoff A V.
Hemorrhagic complications of long-term anticoagulant therapy in 7 patients with
systemic lupus erythematosus and antiphospholipid syndrome.
J Rheumatol.
1997;
24
1716-1718
- 6
The APASS writing Committee .
Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients
with ischemic stroke.
JAMA.
2004;
291
576-584
- 7
Asherson R A, Cervera R, de Groot P G. et al .
Catastrophic antiphospholipid syndrome: international consensus statement on
classification criteria and treatment guidelines.
Lupus.
2003;
12
530-534
- 8
Asherson R A, Cervera R, Piette J C. et al .
Catastrophic antiphospholipid syndrome. Clinical and laboratory features of
50 patients.
Medicine.
1998;
77
195-207
- 9
Asherson R A, Doherty D G, Vergani D, Khamashta M A, Hughes G R.
Major histocompatibility complex assiociations with primary antiphospholipid
syndrome.
Arthrits Rheum.
1992;
35
124-125
- 10
Bentolila S, Fremeaux-Bacchi V, Weiss L, Blouin J, Kazatchkine M D, Piette J C.
High frequency of C4 „null” alleles in primary antiphospholipid syndrome.
Ann Med Interne.
1996;
147
115-116
- 11
Blank M, Faden D, Tincani A. et al .
Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental
antiphospholipid syndrome in naïve mice.
J Autoimmun.
1994;
7
441-455
- 12
Brandt J T, Triplett D A, Alving B, Scharrer I.
Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of
the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific
and Standardisation Committee of the ISTH.
Thromb Haemost.
1995;
74
1185-1190
- 13
Carreno L, Monteagudo I, Lopez L F. et al .
Anticardiolipin antibodies in pediatric patients with human immunodeficiency
virus.
J Rheumatol.
1994;
21
1344-1346
- 14
Cervera R, Khamashta M A, Font J. et al .
Morbidity and mortality in systemic lupus erythematosus during a 5-year period.
A multicenter prospective study of 1,000 patients. European Working Party on
systemic lupus erythematosus.
Medicine.
1999;
78
167-175
- 15
Cervera R, Piette J C, Font J. et al .
Antiphospholipid Syndrome - Clinical and immunological manifestations and patterns
of disease expression in a cohort of 1,000 patients.
Arthritis Rheum.
2002;
46
1019-1027
- 16
Chapman J, Rand J H, Brey R L. et al .
Non-stroke neurological syndromes associated with antiphospholipid antibodies:
evaluation of clinical and experimental studies.
Lupus.
2003;
12
514-517
- 17
Cheng Y, Wong R, Soo Y. et al .
Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone.
N Engl J Med.
2003;
349
831-836
- 18
Crowther M A, Ginsberg J S, Julian J. et al .
A comparison of two intensities of warfarin for the prevention of recurrent
thrombosis in patients with the antiphospholipid antibody syndrome.
N Engl J Med.
2003;
349
1133-1138
- 19
Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M. et al .
Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting
with immune thrombocytopenic purpura: A prospective cohort study.
Blood.
2001;
98
1760-1764
- 20
Erkan D, Asherson R A, Espinosa G. et al .
Catastrophic antiphospholipid syndrome registry project group. Long term outcome
of catastrophic antiphospholipid syndrome survivors.
Ann Rheum Dis.
2003;
62
530-533
- 21
Erkan D, Merill J T, Yazici Y, Sammaritano L, Buyon J P, Lockshin M D.
High thrombosis rate after fetal loss in antiphospholipid syndrome - effective
prophylaxis with aspirin.
Arthritis Rheum.
2001;
44
1466-1467
- 22
Fabris F, Steffan A. et al .
Specific antiplatelet antibodies in patients with antiphospholipid antibodies
and thrombocytopenia.
Eur J Haematol.
1994;
53
232-236
- 23
Facer C A, Agiostratidou G.
High levels of anti-phospholipid antibodies in uncomplicated and severe Plasmodium
falciparum and in P.vivax malaria.
Clin Exp Immunolol.
1994;
95
304-309
- 24
Ferrara D E, Liu X, Espinola R G. et al .
Inhibition of the thrombogenic and inflammatory properties of antiphospholipid
antibodies by fluvastatin in an in vivo animal model.
Arthr Rheum.
2003;
48
3272-3279
- 25
Finazzi G, Brancaccio V, Moia M. et al .
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid
antibodies: a four-year prospective study from the italian registry.
Am J Med.
1996;
100
530-536
- 26
Font J, Jiménez S, Cervera R. et al .
Splenectomy for refractory Evan’s syndrome associated with antiphospholipid
antibodies: report of two cases.
Ann Rheum Dis.
2000;
59
920-923
- 27
Galli M, Barbui T.
Prevalence of different anti-phospholipid antibodies in systemic lupus erythematosus
and their relationship with the antiphospholipid syndrome.
Clin Chem.
2001;
47
985-987
- 28
Galli M, Confurius P, Massau C. et al .
Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma
protein cofactor.
Lancet.
1990;
335
1544-1547
- 29
Galli M, Daldossi M, Barbui T.
Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid
antibodies.
Thromb Haemost.
1994;
71
571-575
- 30
Galli M, Finazzi G, Bevers E M, Barbui T.
Kaolin clotting time and dilute Russel’s viper venome time distinguish between
prothrombin- and ß2-glycoprotein-I-dependent antiphospholipid antibodies.
Blood.
1995;
86
617-623
- 31
Galli M, Luciani D, Bertolini G, Barbui T.
Lupus anticoagulants are stronger risk factor for thrombosis than anticardiolipin
antibodies in the antiphospholipid syndrome: a systematic review of the literature.
Blood.
2003;
101
1827-1832
- 32
Gharavi A E, Harris E N, Asherson R A, Hughes G RV.
Isotype distribution and phospholipid specifity in the antiphospholipid syndrome.
Ann Rheum Dis.
1987;
46
1-6
- 33
Godeau B, Piette J C, Fromont P, Intrator L, Schaeffer A, Bierling P.
Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia
or primary antiphospholipid syndrome.
Br J Haematol.
1997;
98
873-879
- 34
Harris E N, Gharavi A E, Hedge U. et al .
Anticardiolipin antibodies in autoimmune thrombocytopenic purpura.
Br J Haematology.
1985;
59
231-234
- 35
Jung F, Miesbach W, Scharrer I.
Cardiac and cerebral manifestations of antiphospholipid syndrome.
Z Kardiol.
2002;
91
650-658
- 36
Kaburaki J, Kuwana M, Yamamoto M, Kawai S, Ikeda Y.
Clinical significance of anti-annexin V antibodies in patients with systemic
lupus erythematosus.
Am J Hematol.
1997;
54
209-213
- 37
Karassa F B, Bijl M, Davies K A. et al .
Role of Fc-gamma receptor IIA polymorphism in the antiphospholipid syndrome:
an international meta-analysis.
Arthritis Rheum.
2003;
48
1930-1938
- 38
Khamashta M A, Cuadrado M J, Mujic F, Taub N A, Hunt B J, Hughes G RV.
The management of thrombosis in the antiphospholipid-antibody syndrome.
N Engl J Med.
1995;
332
993-997
- 39
Kutteh W H.
Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with
heparin and low-dose aspirin is superior to low-dose aspirin alone.
Am J Obstet Gynecol.
1996;
174
1584-1589
- 40
Lechner K, Pabinger-Fasching I.
Lupus antikoagulant and thrombosis: a study of 25 cases and review of the literature.
Hemostasis.
1985;
15
254-262
- 41
Levine S R, Brey R L, Sawaya K L. et al .
Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome.
Ann Neurol.
1995;
38
119-124
- 42
Levine S R, Salowich-Palm L, Sawaya K L. et al .
IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive
events and death. A prospective cohort study.
Stroke.
1997;
28
1660-1665
- 43
Matsuura H, Igarasha T, Fujimoto M, Ichikawa K, Koike T.
Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease.
Lancet.
1990;
336
117-118
- 44
Mc Neil H D, Simpson R J, Chesterman C N, Krilis S A.
Antiphospholipid antibodies are directed against a complex antigen that includes
a lipid-binding inhibitor of coagulation: beta-2-glycoprotein I (apolipiprotein
H).
Proc Natl Acad Sci USA.
1990;
87
4120-4124
- 45
Merill J T.
Rituximab in antiphospholipid syndrome.
Curr Rheumatol Rep.
2003;
5
381-382
- 46
Meroni P L, Moia M, Derksen R HWM. et al .
Venous thromboembolism in the antiphospholipid syndrome: management guidelines
for secondary prophylaxis.
Lupus.
2003;
12
504-507
- 47
Miesbach W, Scharrer I, Asherson R A.
Recurrent life-threatening thromboembolism and catastrophic antiphospholipid
syndrome in a patient despite sufficient oral anticoagulation.
Clin Rheum.
2004;
23
256-261
- 48
Muir K W, Squire I B, Alwan W, Lees K R.
Anticardiolipin antibodies in an unselected stroke population.
Lancet.
1994;
344
452-464
- 49
Munoz-Rodríguez F J, Font J. et al .
Clinical study and follow-up of 100 patients with the antiphospholipid syndrome.
Semin Arthritis Rheum.
1999;
29
182-190
- 50
Ogasawara M, Aoki K, Matsuura E, Sasa H, Yagami Y.
Anti beta 2 glycoprotein I antibodies and lupus anticoagulant in patients with
recurrent pregnancy loss: prevalence and clinical significance.
Lupus.
1996;
5
587-592
- 51
Pasquier E, Amiral J, de Saint Martin L, Mottiert D.
A cross sectional study of antiphospholipid-protein antibodies in patients with
venous thromboembolism.
Thromb Haemost.
2001;
86
538-542
- 52
Pattison N S, Chamley L W, McKay E J, Liggins G C, Butler W S.
Antiphospholipid antibodies in pregnancy: prevalence and clinical associations.
Br J Obstet Gynaecol.
1993;
100
909-913
- 53
Pengo V, Biasiolo A, Brocco T, Tonett S, Ruffatti A.
Autoantibodies to phospholipid -binding plasma proteins in patients with thrombosis
and phospholipid-reactive antibodies.
Thromb Haemost.
1996;
75
721-724
- 54 Petri M. Classification and epidemiology of the antiphospholipid syndrome. First
edition Amsterdam: Elsevier In Asherson A, Cervera R, Piette JC, Shoenfeld Y,
editors. The antiphospholipid syndrome II 2002: 11-20
- 55
Petri M.
Detection of coronary artery disease and the role of traditional risk factors
in the Hopkins Lupus Cohort.
Lupus.
2000;
9
170-175
- 56
Rand J H, Wu X X, Andree H AM. et al .
Antiphospholipid antibodies accelerate plama coagulation by inhibiting annexin-V
binding to phospholipids: a „Lupus procoagulant” phenomen.
Blood.
1998;
92
1652-1660
- 57
Rosove M H, Brewer P MC.
Antiphospholipid thrombosis: clinical course after the first thrombotic event
in 70 patients.
Ann Intern Med.
1992;
117
303-308
- 58
Salonen J T, Yla-Herttuala S, Yamamoto R. et al .
Autoantibody against oxidized LDL and progression of carotid atherosclerosis.
Lancet.
1992;
339
883-887
- 59
Schmidt R, Auer-Grumbach P, Fazekas F, Offenbacher H, Kapeller P.
Anticardiolipin antibodies in normal subjects: Neuropsychological correlates
and MRI findings.
Stroke.
1995;
26
749-754
- 60
Sebastiani G D, Galeazzi M, Tincani A. et al .
HLA-DPB1 alleles association of anticardiolipin and anti-beta 2GPI antibodies
in a large series of European patients with systemic lupus erythematosus.
Lupus.
2003;
12
560-563
- 61
Selva-O’Callaghan A, Ordi-Ros J, Monegal-Ferran F, Martinez N, Cortes-Hernandez F,
Vilardell-Tarres M.
IgA anticardiolipin antibodies - relation with other antiphospholipid antibodies
and clinical significance.
Thromb Haemost.
1998;
79
282-285
- 62
Shah N M, Khamashta M A, Atsumni T, Hughes G R.
Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of
52 patients.
Lupus.
1998;
7
3-6
- 63
Shi W, Krilis S A, Chong B H, Gordon S, Chesterman C N.
Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy
population.
Aust N Z J Med.
1990;
20
231-236
- 64
Stasi R, Stipa E, Masi M. et al .
Long-term observation of 208 adults with chronic idiopathic thrombocytopenic
purpura.
Am J Med.
1995;
98
436-442
- 65
Sugi T, Katsunuma J, Izumi S, McIntyre J A, Makino T.
Prevalence and heterogenity of antiphosphatidylethanolamine antibodies in patients
with recurrent early pregnancy losses.
Fertil Steril.
1999;
71
1060-1065
- 66
Tincani A, Branch W, Levy R A. et al .
Treatment of pregnant patients with antiphospholipid syndrome.
Lupus.
2003;
12
524-529
- 67
Tsapanos V, Kanellopoulos N. et al .
Anticardiolipin antibodies levels in healthy pregnant and non-pregnant woman.
Arch Gynecol Obstet.
2000;
263
111-115
- 68
Wilson W A, Gharavi A E, Koike T. et al .
International consensus statement on preliminary classification criteria for
definite antiphospholipid syndrome: report of an international workshop.
Arthritis Rheum.
1999;
42
1309-1311
- 69
Wisbey H L, Klestov A C.
Thrombocytopenia corrected by warfarin in antiphospholipid syndrome.
J Rheum.
1996;
23
769-771
- 70
Ziporen L, Shoenfeld Y. et al .
Neurological dysfunction and hyperactive behavior associated with antiphospholipid
antibodies.
J Clin Invest.
1997;
100
613-619
Dr. med. Wolfgang Miesbach
Hämostaseologie, Zentrum der Inneren Medizin, Medizinische Klinik III, Universitäts-Klinik
Frankfurt/Main
Theodor-Stern-Kai 7
60590 Frankfurt
Phone: 069/63015051
Fax: 069/63016738
Email: miesbach@em.uni-frankfurt.de
